surmount 1 tirzepatide SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 👀 📉Sustained weight loss of 22.9% or an average 54lbs over 3 years 🔽94% reduction in risk of progression to diabetes. Number SURPASS to SURMOUNT: The Tirzepatide

Conu comme un agoniste trois rcepteurs, le Retatrutide active simultanment les rcepteurs GLP-1, GIP et glucagon, produisant un effet synergique sur la rgulation mtabolique, la suppression de lapptit, lactivit de linsuline et lutilisation des graisses

Retatrutide is a weekly injection that acts on three hormone receptors to support weight loss

This may provide new therapeutic strategies for restoring the damaged dopaminergic system in PD patients

That second number is the one that matters

A 40-week study of Mounjaro tested the drug with participants with type 2 diabetes

[Melatonin and cardiovascular performance regulation] [PMID: 11521378] Laboratory literature summary: [Melatonin and cardiovascular performance regulation]